Boston Scientific CorpBSX
Mentioned
Impact on stocks 2
Brain-Computer Interface
Boston Scientific CorpFinancials
Truist Financial CorpTFC
Mentioned
Boston Scientific CorpTruist Financial CorpTruist Securities lowered its price target on Boston Scientific from $85 to $64 while maintaining a Buy rating, citing a slowdown in demand for the company's Watchman heart device. Analyst Richard Newitter pointed to a shift in clinical practice where doctors increasingly combine Watchman procedures with other cardiac treatments in a single appointment, reducing standalone procedure volumes. Boston Scientific CEO Michael Mahoney disclosed the trend at a conference on May 27 and told investors to expect Watchman revenue to remain essentially flat from the first quarter through the second quarter and likely into the third quarter of 2026. The Watchman is a small implant designed to reduce stroke risk in patients with non-valvular atrial fibrillation as an alternative to blood thinners.
Boston Scientific CorpTruist Financial Corp